Stock Market Reviews

ACET (Adicet Bio, Inc.) News

Get the latest news, insights, and market updates on ACET (Adicet Bio, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
  Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Sep 30, 2025 - $ACET
• Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
  REDWOOD CITY, Calif. & BOSTON, September 30, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on September 30, 2025.
  Sep 30, 2025 - $ACET
• Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
  REDWOOD CITY, Calif. & BOSTON, September 02, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York.
  Sep 2, 2025 - $ACET
• Adicet Bio (ACET) Upgraded to Buy: Here's Why
  Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Aug 12, 2025 - $ACET
• MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
  MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 4, MaxCyte, Inc. (NASDAQ:MXCT) announced signing a strategic platform license with Adicet Bio, Inc. Adicet focuses on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. As part of this agreement, Adicet gets non-exclusive rights to […]
  Aug 11, 2025 - $ACET
• Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
  REDWOOD CITY, Calif. & BOSTON, August 07, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2025.
  Aug 7, 2025 - $ACET
• MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
  ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2025 financial results and updated its 2025 guidance. Second Quarter and Recent Highlights Core business revenue of $8.2 million in the second quarter of 2025, an increase of 8% over the
  Aug 6, 2025 - $ACET
• Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
  REDWOOD CITY, Calif. & BOSTON, August 05, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 45th Annual Canaccord Genuity Growth Conference being held from August 12-14, 2025 in Boston.
  Aug 5, 2025 - $ACET
• MaxCyte Signs Platform License Agreement with Adicet Bio
  MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced it has signed a strategic platform license (SPL) with Adicet Bio, I
  Aug 4, 2025 - $ACET
• Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001
  Participants who are enrolled will be given a dose of ADI-001, followed by a 28-day dose-limiting toxicity window.
  Jul 25, 2025 - $ACET